Stock Events

Stock Events

Wuxi Biologics (Cayman) 

฿3.54
0
-฿0.06-1.67% Today

Statistics

Day High
3.56
Day Low
3.5
52W High
4.28
52W Low
3.16
Volume
106,110
Avg. Volume
-
Mkt Cap
14.4B
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

24MarExpected
Q2 2025
Q4 2025
2.05
2.34
2.63
2.92
Expected EPS
2.9244040559999998
Actual EPS
N/A

Financials

17.96%Profit Margin
Profitable
2019
2020
2021
2022
2023
2024
177.89BRevenue
31.96BNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow WUXI06.BK. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Sartorius
SARTF
Mkt Cap17.93B
Sartorius Stedim Biotech is a supplier of equipment and services for biopharmaceutical manufacturing, competing in the bioprocessing space with Wuxi Biologics.
Charles River Laboratories International
CRL
Mkt Cap9.07B
Charles River Laboratories offers a broad range of services to support the pharmaceutical and biotech industries, including biologics testing services.
Thermo Fisher Scientific
TMO
Mkt Cap195.7B
Thermo Fisher Scientific provides bioproduction and bioprocessing products and services, competing with Wuxi Biologics in the supply of critical biomanufacturing technologies.
Danaher
DHR
Mkt Cap137.82B
Danaher, through its subsidiaries like Cytiva, competes in the bioprocessing space by providing technologies and services for biomanufacturing.
Bio-Rad Laboratories
BIO
Mkt Cap8.07B
Bio-Rad Laboratories offers products and services in the field of life science research and clinical diagnostics, competing in the biologics tools and services market.
IQVIA
IQV
Mkt Cap29.95B
IQVIA provides advanced analytics, technology solutions, and contract research services to the life sciences industry, competing in the broader biopharmaceutical services market.
Pfizer
PFE
Mkt Cap156.77B
Pfizer, through its contract manufacturing organization Pfizer CentreOne, competes in the biologics manufacturing and development services sector.
Gilead Sciences
GILD
Mkt Cap170.84B
Gilead Sciences, while primarily a biopharmaceutical company, competes for resources, talent, and market share in the biologics sector, particularly in areas of overlapping therapeutic interest.

About

WuXi Biologics (Cayman) Inc. provides end-to-end solutions and services for biologics discovery, development and manufacturing in the People's Republic of China, North America, Europe, and internationally. The company also engages in the provision of consultation services in relation to the biopharmaceutical technology, international sales contracting services, testing and development of testing technologies, sales and marketing services, and biologics clinical and manufacturing services; production and sale of medicals; vaccine CDMO and related business; and material supplier activities. WuXi Biologics (Cayman) Inc. has strategic partnership with ImmuneOncia Therapeutics, Legochem Biosciences Inc, Worg Pharma, OncoC4, and Exelixis Inc. The company was incorporated in 2014 and is headquartered in Wuxi, China.
Show more...
CEO
Dr. Ge Li Ph.D.
Employees
12575
Country
United States
ISIN
TH0842123109

Listings

BK
TH
WUXI13.BK
MU
DE
1FW1.MU
STU
DE
1FW1.STU
STU
DE
1FW2.STU

0 Comments

Share your thoughts

FAQ

What is Wuxi Biologics (Cayman) stock price today?▼
The current price of WUXI06.BK is ฿3.54 THB — it has decreased by -1.67% in the past 24 hours. Watch Wuxi Biologics (Cayman) stock price performance more closely on the chart.
What is Wuxi Biologics (Cayman) stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Wuxi Biologics (Cayman) stocks are traded under the ticker WUXI06.BK.
What is Wuxi Biologics (Cayman) market cap?▼
Today Wuxi Biologics (Cayman) has the market capitalization of 14.4B
When is the next Wuxi Biologics (Cayman) earnings date?▼
Wuxi Biologics (Cayman) is going to release the next earnings report on August 26, 2026.
What is Wuxi Biologics (Cayman) revenue for the last year?▼
Wuxi Biologics (Cayman) revenue for the last year amounts to 177.89B THB.
What is Wuxi Biologics (Cayman) net income for the last year?▼
WUXI06.BK net income for the last year is 31.96B THB.
How many employees does Wuxi Biologics (Cayman) have?▼
As of April 23, 2026, the company has 12,575 employees.
In which sector is Wuxi Biologics (Cayman) located?▼
Wuxi Biologics (Cayman) operates in the Health & Wellness sector.
When did Wuxi Biologics (Cayman) complete a stock split?▼
Wuxi Biologics (Cayman) has not had any recent stock splits.
Where is Wuxi Biologics (Cayman) headquartered?▼
Wuxi Biologics (Cayman) is headquartered in Wuxi, United States.